期刊文献+

核苷酸适体在靶向给药系统中的应用进展

Application progress of nucleic acid aptamers in targeted drug delivery system
下载PDF
导出
摘要 适体,即体外合成筛选得到的能特异性地与靶分子结合的一段寡核苷酸序列。由于其独特的性质,在靶向给药系统中有着广阔的应用前景,目前已成为靶向给药研究领域的热点。综述了适体在靶向给药系统中的优势及其应用进展,并对其应用前景和面临的问题进行分析。 Aptamers are single stranded oligonucleotides that have high affinity and specificity towards a wide range of target molecules .Owing to the indispensable advantages ,aptamers have wildly prospects and have become a research hotspot in targeted drug delivery system (TDDS) .In this article ,application advantage and progress of aptamers in TDDS were briefly reviewed ,the problems and prospects were also discussed .
出处 《药学实践杂志》 CAS 2015年第6期490-493,532,共5页 Journal of Pharmaceutical Practice
基金 国家自然科学基金项目(No.81170060)
关键词 核苷酸适体 靶向给药 应用进展 nucleic acid aptamers targeted drug delivery application progress
  • 相关文献

参考文献29

  • 1Tan W, Wang H, Chen Y, et al. Molecular aptamers for drug delivery[J]. Trends Bioteehnol, 2011, 29 (12) :634 640.
  • 2Ozalp VC, Eyldogan F, Oktem HA. Aptamer-gated nanop- articles for smart drug delivery[J]. Pharmaceuticals, 2011, 4 (8): 1137-1157.
  • 3Taouji S, Dausse E, Evad6 L, et al. Advances in binder i- dentification and characterisation:the case of oligonucleotide aptamers[J]. N Biotechnol, 2012, 29(5): 550-554.
  • 4Famulok M, Hairtig JS, Mayer G. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy [J]. Chem Rev, 2007, 107(9): 3715-3743.
  • 5Lupold SE, Hicke BJ, Lin Y, et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific mem- braneantigen[J].Cancer Res, 2002, 62(14): 4029-4033.
  • 6Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparti- cle-aptamer bioconjugates a new approach for targeting pros- tate cancer cells[J]. Cancer Res, 2004, 64(21) : 7668-7672.
  • 7Bagalkot V, Farokhzad OC, Langer R, et al. An aptamer- doxorubicin physical conjugate as a novel targeted drug-deliv- ery platform[J]. AngewChemlnt Ed, 2006, 45(48): 8149- 8152.
  • 8Kraus E, James W, Barclay AN. Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4-F T lym- phocyte function[J]. J lmmunol, 1998, 160(11).. 5209- 5212.
  • 9Guo S, Tschammer N, Mohammed S, et al. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA[J]. Hum Gene Ther, 2005, 16(9): 1097-1110.
  • 10Khaled A, Guo S, Li F, et al. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic mol- ecules to cancer cells using RNA nanotechnology[J]. Nano Lett, 2005, 5(9): 1797 1808.

二级参考文献23

  • 1LEE P, WANG CC, ADAMIS AP, et al. Ocular neovasculafization: an epidemiologic review [ J ]. Surv Ophthalmol, 1998,43 (3) :245 -269.
  • 2Treatment of age-related maeular degeneration with photodynamie therapy study group. Photodynamie therapy of subfoveal ehoroidal neovaseularization in age-related maeular degeneration with verteporfin : two-year results of 2 randomized clinical trials-tap report 2 [ J ]. Arch Ophthalmol,2001,119 ( 2 ) : 198 - 207.
  • 3ARROYO J. Age-related maculax degeneration [ EB/OL ]. ( 2005 - 06-16). http://www uptodateonline. com.
  • 4MILLER DW, JOUSSEN AM, HOLZ FG. The molecular mechanisms of neovascular age-related macular degeneration [ J ]. Ophthalmologe, 2003,100 (2) :92 - 96.
  • 5ZARBIN MA. Current concepts in the pathogenesis of age-related macular degeneration [J]. Arch Opkthalmol, 2004, 122 ( 4 ) : 598 - 614.
  • 6GRAGOUDAS ES, ADAMIS AP, CUNNINGHAM ET, Jr. , et al. For the VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration [ J ]. N Engl J Med, 2004,351 ( 27 ) : 2805 - 2816.
  • 7TUCKER CE, CHEN LS, JUDKINS MB, et al. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys [J]. J Chromatogr B Biomed Sci Appl, 1999,732 ( 1 ) :203 - 212.
  • 8BELL C, LYNAM E, LANDFAIR DJ, et al. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro [J]. In Vitro Cell Dev Biol Anita, 1999, 35 (9) :533 -542.
  • 9Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer ( EYE001 ) for the treatment of exudative age-related macular degeneration [ J ]. Retina, 2002,22(2) :143 - 152.
  • 10Eyetech Pharmaceuticals Inc./Pfizer Inc. Product information : Macugeu( pegaptauib sodium injection) 0.3 mg[ EB/OL]. [ 2005 - 06 - 08 ]. http ://www. macugen. com.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部